{"log_id": 4762874179961787501, "direction": 0, "words_result_num": 30, "words_result": [{"probability": {"variance": 2e-06, "average": 0.999102, "min": 0.993499}, "location": {"width": 771, "top": 203, "height": 28, "left": 224}, "words": "周。因此,如果可能医师应该在停用曲妥珠单抗之后的24周内避免使用以蒽环类"}, {"probability": {"variance": 0.000355, "average": 0.995505, "min": 0.886634}, "location": {"width": 765, "top": 246, "height": 27, "left": 222}, "words": "药物为基础的治疗。如果在这时间之前需要使用蒽环类药物,须仔细监测心功能"}, {"probability": {"variance": 8e-06, "average": 0.999158, "min": 0.98278}, "location": {"width": 764, "top": 311, "height": 27, "left": 223}, "words": "对接受高累积剂量伊达比星及具有高危风险的患者应进行严格的心脏功能的监测"}, {"probability": {"variance": 2e-06, "average": 0.99932, "min": 0.991779}, "location": {"width": 741, "top": 354, "height": 29, "left": 222}, "words": "然而无论是否存在心脏毒性风险因素,累积剂量较低时仍有可能发生心脏毒性"}, {"probability": {"variance": 1e-06, "average": 0.999225, "min": 0.993981}, "location": {"width": 784, "top": 419, "height": 28, "left": 223}, "words": "婴儿和儿童似乎对伊达比星诱发的心脏毒性更加易感,必须长期进行定期的心脏功"}, {"probability": {"variance": 9e-06, "average": 0.997531, "min": 0.993221}, "location": {"width": 69, "top": 464, "height": 25, "left": 222}, "words": "能监测"}, {"probability": {"variance": 5e-05, "average": 0.997219, "min": 0.961903}, "location": {"width": 611, "top": 526, "height": 27, "left": 223}, "words": "伊达比星和其他蒽环类或蒽二酮类药物的毒性作用可能是累加的"}, {"probability": {"variance": 1e-06, "average": 0.998956, "min": 0.996464}, "location": {"width": 782, "top": 590, "height": 27, "left": 225}, "words": "血液毒性伊达比星是强烈的骨髓抑制剂。所有患者使用治疗剂量的本品都会出现"}, {"probability": {"variance": 0, "average": 0.999569, "min": 0.996796}, "location": {"width": 763, "top": 632, "height": 28, "left": 224}, "words": "严重的骨髓抑制。使用伊达比星前及每个周期都应进行血液学检查,包括白细胞"}, {"probability": {"variance": 0.005598, "average": 0.984782, "min": 0.54395}, "location": {"width": 753, "top": 674, "height": 27, "left": 246}, "words": "WBC)计数。剂量依赖性的、可逆的白细胞减少和/或粒细胞减少(中性粒细胞"}, {"probability": {"variance": 0, "average": 0.999491, "min": 0.99722}, "location": {"width": 784, "top": 716, "height": 28, "left": 225}, "words": "减少)是伊达比星主要的血液学毒性,并且是伊达比星最常见的急性剂量限制性毒"}, {"probability": {"variance": 0, "average": 0.999353, "min": 0.996772}, "location": {"width": 763, "top": 759, "height": 29, "left": 224}, "words": "性。白细胞减少或中性粒细胞减少通常很严重,血小板减少和贫血也有可能发生"}, {"probability": {"variance": 2e-06, "average": 0.999282, "min": 0.991913}, "location": {"width": 782, "top": 801, "height": 28, "left": 225}, "words": "中性粒细胞和血小板计数一般在用药后的10至14天达到最低点,但大部分患者的"}, {"probability": {"variance": 0.000142, "average": 0.996577, "min": 0.933326}, "location": {"width": 672, "top": 843, "height": 31, "left": 226}, "words": "细胞计数会在第3周内恢复至正常范围。严重骨髓抑制的临床表现包括"}, {"probability": {"variance": 0, "average": 0.984894, "min": 0.984894}, "location": {"width": 29, "top": 842, "height": 27, "left": 961}, "words": "感"}, {"probability": {"variance": 0.004667, "average": 0.984576, "min": 0.625464}, "location": {"width": 625, "top": 886, "height": 28, "left": 225}, "words": "染、脓毒血症/败血症、感染性休克、出血、组织缺氧、甚至死山"}, {"probability": {"variance": 0, "average": 0.725477, "min": 0.725477}, "location": {"width": 134, "top": 875, "height": 66, "left": 827}, "words": "食"}, {"probability": {"variance": 0, "average": 0.981166, "min": 0.981166}, "location": {"width": 38, "top": 902, "height": 31, "left": 992}, "words": ">"}, {"probability": {"variance": 0.011265, "average": 0.962259, "min": 0.580661}, "location": {"width": 777, "top": 948, "height": 35, "left": 225}, "words": "继发性白血病有报道在使用蒽环类药物包括伊达比星的患者中出现了继发性白血"}, {"probability": {"variance": 0.004824, "average": 0.985324, "min": 0.578646}, "location": {"width": 784, "top": 992, "height": 31, "left": 224}, "words": "病,可伴或不伴白血病前期症状。下列情况下出现继发性白血病更为常见)当与作"}, {"probability": {"variance": 5e-06, "average": 0.998798, "min": 0.991152}, "location": {"width": 775, "top": 1036, "height": 30, "left": 226}, "words": "用机制为破坏DNA结构的抗癌药物联合使用时,或患者既往多次使用细胞毒药物"}, {"probability": {"variance": 3.8e-05, "average": 0.998275, "min": 0.963232}, "location": {"width": 754, "top": 1078, "height": 30, "left": 223}, "words": "时,或者蒽环类药物治疗剂量有所提升时。此类白血病的潜伏期通常为1~3年"}, {"probability": {"variance": 3e-06, "average": 0.998865, "min": 0.991112}, "location": {"width": 777, "top": 1142, "height": 28, "left": 228}, "words": "胃肠道伊达比星会引起呕吐反应。粘膜炎(主要是口腔炎,食管炎少见)通常会"}, {"probability": {"variance": 4e-06, "average": 0.999058, "min": 0.989655}, "location": {"width": 782, "top": 1183, "height": 30, "left": 227}, "words": "发生在给药后的早期,如果情况严重,几天后可能会进展为粘膜溃疡。绝大多数的"}, {"probability": {"variance": 5e-06, "average": 0.998789, "min": 0.991398}, "location": {"width": 308, "top": 1228, "height": 27, "left": 227}, "words": "患者在给药后的第三周得以恢复"}, {"probability": {"variance": 2e-06, "average": 0.999062, "min": 0.994407}, "location": {"width": 783, "top": 1289, "height": 33, "left": 229}, "words": "有时,对于患急性白血病或其他疾病或接受已知会引起胃肠道并发症药物的患者口"}, {"probability": {"variance": 0.000299, "average": 0.995633, "min": 0.895352}, "location": {"width": 784, "top": 1331, "height": 33, "left": 227}, "words": "服伊达比星,偶尔会发生严重的胃肠道不良反应(如穿孔或出血)。对于出血和或穿"}, {"probability": {"variance": 1.2e-05, "average": 0.999018, "min": 0.978946}, "location": {"width": 763, "top": 1375, "height": 32, "left": 227}, "words": "孔风险增高的活动性胃肠道疾病患者,医生必须权衡口服伊达比星的益处与风险"}, {"probability": {"variance": 0.000259, "average": 0.986669, "min": 0.954618}, "location": {"width": 128, "top": 1545, "height": 21, "left": 301}, "words": "No:20100128"}, {"probability": {"variance": 0.001332, "average": 0.983115, "min": 0.894127}, "location": {"width": 103, "top": 1537, "height": 24, "left": 574}, "words": "第7页共11页"}], "language": 3}